Sirona posted profits of $36.2 million, or 65¢ per share, on sales of $278.6 million for the 3 months ended Sept. 30. That’s a profit gain of 4.3% on sales growth of 12.6% compared with the same period last year. Adjusted to exclude 1-time items, earnings per share were 81¢, behind Wall Street’s 95¢ expectation.
For its fiscal year, the New York City-based medical device company posted profits of $146.7 million, or $2.61 per share, on sales of $1.1 billion for the year. That’s a profit gain of 9.6% on sales growth of 12.5% compared to the previous fiscal year.
“In fiscal 2014 we continue to see strong demand for our products and expect to generate solid bottom line leverage. The 4% to 6% revenue guidance range reflects the difficult comparisons created by this year’s 20% constant currency growth in our two largest markets, the U.S. and Germany,” president and CEO Jeffrey Slovin said in prepared remarks.
The news sent SIRO shares down 3.8% when it was reported on Nov. 22. Sirona shares were trading at $67.75 a piece as of about 2 p.m. today, down 3.4%.